Dr. Michael Vishal Jaglal, MD

Dr. Jaglal practices at Moffitt Cancer Center at International Plaza - HOPD in Tampa, Florida.

Dr. Jaglal's NPI, 1417024746, was assigned on November 30, 2006. Dr. Jaglal graduated from St. George's University School of Medicine in 2005. Dr. Jaglal holds Florida license ME101760.

Dr. Jaglal's primary practice is Moffitt Cancer Center at International Plaza - HOPD, at 4101 Jim Walter Boulevard, Tampa, FL 33607.

Dr. Jaglal's primary practice is Moffitt Cancer Center at International Plaza - HOPD in Tampa, Florida. Dr. Jaglal is also affiliated with Tampa General Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Jaglal to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jaglal practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Jaglal's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Jaglal is board certified in hematology by the American Board of Internal Medicine. Dr. Jaglal is licensed in Florida.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer and lymphoma among the conditions Dr. Jaglal treats.

CMS data shows 584 Medicare services from Dr. Jaglal across 5 procedure codes in 2024, for 261 Medicare patients. Medicare paid $39,583 for them.

CMS counts 261 Medicare patients who saw Dr. Jaglal in 2024. The largest group is 65 to 74, with 104 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jaglal's median patient age at 60, with 57% women.

In 2024, Dr. Jaglal wrote 1,272 Medicare Part D claims for 131 patients. 73% of them were for generic drugs. CMS names the drug for 959 of them, across 31 drugs with 11 or more claims each, at $1,129,133 in total drug cost. In 2023, CMS named 953 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Jaglal for performance year 2024, reported as part of a group. Dr. Jaglal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jaglal as offering telehealth.

Dmand AI links 48 papers to Dr. Jaglal, published from 2009 to 2025. 2024 was the busiest year, with 5. The most frequent topics are Hematopoietic Stem Cell Transplantation, Administration, Oral and Anticoagulants. Dr. Jaglal has published most often in J Clin Med. Dr. Jaglal's most frequent co-authors are Nathan I. Visweshwar, MD, Damian A. Laber, MD and Lubomir Sokol, MD.

CMS Open Payments shows 90 general payments to Dr. Jaglal from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 68% of the total. Alexion Pharmaceuticals, Inc. paid the most, $27,056.

Dr. Jaglal graduated from St. George's University School of Medicine in 2005.

Dr. Jaglal is in network with 8 carriers, including Excellus BlueCross BlueShield, United Healthcare and Elevance. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.